. 2018 Jan 2;9(6):7162–7174. doi: 10.18632/oncotarget.23852

Table 3. Results from compartmental modeling and Logan graphical analysis of the PET data of the PBMC implant.

	Xenograft TACs				Plasma TACs
Parameter	V_T (2TCM)	BP_ND (2TCM)	V_T (Logan)	AUC	Half- life
					T1	T2
Wild-type [¹⁸F]FB-IL2	0.40 ± 0.20	10.6 ± 2.9	0.47 ± 0.02	50.1 ± 3.7	0.7 ± 0.2 (17 %)	7.1 ± 2.6 (83%)
Mutant [¹⁸F]FB-IL2v	0.18 ± 0.04	4.3 ± 0.5	0.21 ± 0.01	40.7 ± 1.9	2.1 ± 1.3 (14%)	17.6 ± 1.3 (86%)
Mutant [¹⁸F]FB-IL2v	p < 0.01	p < 0.001	p < 0.01	p < 0.05	NS	p < 0.01
Mutant [¹⁸F]FB-IL2v + 5 mg/kg wild-type IL2	0.07 ± 0.02	2.2 ± 0.7	0.10 ± 0.01	31.7 ± 0.4	1.1 ± 0.6 (14%)	38.2 ± 1.6 (86%)
Mutant [¹⁸F]FB-IL2v + 5 mg/kg wild-type IL2	p < 0.001	p < 0.001	p < 0.001	p < 0.05	NS	p < 0.01

Bi-exponential clearance of the tracer was observed in plasma. The data represent the mean ± standard deviation.